Dencker S J, Wilhelmson G, Carlsson E, Bereen F J
J Int Med Res. 1978;6(5):395-400. doi: 10.1177/030006057800600508.
Sixty in-patient alcoholics, presenting with an alcohol withdrawal syndrome after at least one week's drinking bout, were randomly allocated to fixed dose regimens of either piracetam or chlormethiazole in a one-week double-blind trial. The patients were studied in respect to physical and biochemical parameters as well as symptom reduction and side-effects. The battery of rating scales demonstrated a good symptom reduction in both drug groups. On the whole a small tendency to more symptom items being reduced on piracetam in comparison with chlormethiazole was found. But the tree items, sleep disturbances, decreased libido at the initial phase, and the staff's assessment showed statistically significant differences in favour of chlormethiazole. This study demonstrated that piracetam was just as efficient as chlormethiazole in patients not requiring sedation.
60名住院酒精成瘾者,在至少一周的饮酒发作后出现酒精戒断综合征,在一项为期一周的双盲试验中被随机分配到服用固定剂量的吡拉西坦或氯美噻唑的治疗方案中。对患者的身体和生化参数、症状减轻情况及副作用进行了研究。一系列评定量表显示,两个药物组的症状都有明显减轻。总体而言,与氯美噻唑相比,服用吡拉西坦的患者在更多症状项目减轻方面有轻微的趋势。但睡眠障碍、初期性欲减退和工作人员评估这三个项目显示,在统计学上氯美噻唑有显著优势。这项研究表明,在不需要镇静的患者中,吡拉西坦与氯美噻唑的疗效相当。